The newly appointed head of medicine approvals at the US Food & Drug Administration has insisted that science rather than politics or pricing is behind the growing difficulties facing new pharmaceuticals attempting to reach the market.

Janet Woodcock, head of the Centre for Drug Evaluation and Research, one of the most senior jobs at the FDA, rejected claims from drug companies that her unit was rejecting new medicines because the agency was too risk-averse.